Janssen Licenses Metabolic Drug from Hanmi Pharma

Janssen Pharmaceuticals, Inc. has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies from Hanmi Pharmaceutical Co. The agreement includes HM12525A, a biologic expected to enter Phase II studies next year.
 
HM12525A is an oxyntomodulin-based therapy (GLP-1/glucagon receptor dual agonist) that has been shown to improve multiple metabolic parameters that lead to improved blood glucose, body weight, and insulin sensitivity, as a once weekly therapy.
 
“We are very excited about this agreement with Hanmi and the potential of HM12525A to improve therapeutic options for people living with metabolic diseases,” said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen. “Our deep scientific expertise and demonstrated clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases. We look forward to developing this potential best-in-class therapy, which allows us to build on our success in diabetes and strengthen our metabolism portfolio.”